These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29761231)

  • 1. New Equilibrium Models of Drug-Receptor Interactions Derived from Target-Mediated Drug Disposition.
    Peletier LA; Gabrielsson J
    AAPS J; 2018 May; 20(4):69. PubMed ID: 29761231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo potency revisited - Keep the target in sight.
    Gabrielsson J; Peletier LA; Hjorth S
    Pharmacol Ther; 2018 Apr; 184():177-188. PubMed ID: 29024741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lost in translation: What's in an EC
    Gabrielsson J; Peletier LA; Hjorth S
    Eur J Pharmacol; 2018 Sep; 835():154-161. PubMed ID: 30036536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Turn On, Tune In, Turnover! Target Biology Impacts In Vivo Potency, Efficacy, and Clearance.
    Gabrielsson J; Hjorth S
    Pharmacol Rev; 2023 May; 75(3):416-462. PubMed ID: 36627211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect.
    Kenakin T
    ACS Chem Biol; 2009 Apr; 4(4):249-60. PubMed ID: 19193052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons of basic target-mediated drug disposition (TMDD) and ligand facilitated target removal (LFTR).
    Peletier LA; Jansson-Löfmark R; Gabrielsson J
    Eur J Pharm Sci; 2021 Jul; 162():105835. PubMed ID: 33848634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systems pharmacology - Towards the modeling of network interactions.
    Danhof M
    Eur J Pharm Sci; 2016 Oct; 94():4-14. PubMed ID: 27131606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting ligand-receptor interactions for development of cancer therapeutics.
    Kim JW; Cochran JR
    Curr Opin Chem Biol; 2017 Jun; 38():62-69. PubMed ID: 28371692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand-receptor interaction platforms and their applications for drug discovery.
    Fang Y
    Expert Opin Drug Discov; 2012 Oct; 7(10):969-88. PubMed ID: 22860803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic Steady-States Highlight Interesting Target-Mediated Disposition Properties.
    Gabrielsson J; Peletier LA
    AAPS J; 2017 May; 19(3):772-786. PubMed ID: 28144911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating drug potency in the competitive target mediated drug disposition (TMDD) system when the endogenous ligand is included.
    Alaybeyoglu B; Cheng HWJ; Doshi KA; Makani V; Stein AM
    J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):447-464. PubMed ID: 33558979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor binding kinetics equations: Derivation using the Laplace transform method.
    Hoare SRJ
    J Pharmacol Toxicol Methods; 2018; 89():26-38. PubMed ID: 28818556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Extended Model Including Target Turnover, Ligand-Target Complex Kinetics, and Binding Properties to Describe Drug-Receptor Interactions.
    Peletier LA
    Methods Mol Biol; 2022; 2385():19-46. PubMed ID: 34888714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mathematical description of drug-target interactions: application to biologics that bind to targets with two binding sites.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2018 Feb; 45(1):23-34. PubMed ID: 28918570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autocrine ligand binding to cell receptors. Mathematical analysis of competition by solution "decoys".
    Forsten KE; Lauffenburger DA
    Biophys J; 1992 Feb; 61(2):518-29. PubMed ID: 1312367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-kinetic relationships that control the residence time of drug-target complexes: insights from molecular structure and dynamics.
    Lu H; Iuliano JN; Tonge PJ
    Curr Opin Chem Biol; 2018 Jun; 44():101-109. PubMed ID: 29986213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets.
    Davda JP; Hansen RJ
    MAbs; 2010; 2(5):576-88. PubMed ID: 20676036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
    Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.